# Bioventus Inc. (BVS) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Bioventus Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/BVS/mda/fy2025/): filed 2026-03-05; accession 0001665988-26-000011 (https://www.sec.gov/Archives/edgar/data/1665988/000166598826000011/bvs-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/BVS/mda/fy2024/): filed 2025-03-11; accession 0001628280-25-011831 (https://www.sec.gov/Archives/edgar/data/1665988/000162828025011831/bvs-20241231.htm)
- [FY 2023 MD&A](/company/BVS/mda/fy2023/): filed 2024-03-12; accession 0001628280-24-010376 (https://www.sec.gov/Archives/edgar/data/1665988/000162828024010376/bvs-20231231.htm)
- [FY 2022 MD&A](/company/BVS/mda/fy2022/): filed 2023-03-31; accession 0001628280-23-010151 (https://www.sec.gov/Archives/edgar/data/1665988/000162828023010151/bvs-20221231.htm)
- [FY 2021 MD&A](/company/BVS/mda/fy2021/): filed 2022-03-11; accession 0001628280-22-005816 (https://www.sec.gov/Archives/edgar/data/1665988/000162828022005816/bvs-20211231.htm)

Back to /company/BVS/